John Ervin

1.6k total citations · 1 hit paper
20 papers, 677 citations indexed

About

John Ervin is a scholar working on Epidemiology, Immunology and Rheumatology. According to data from OpenAlex, John Ervin has authored 20 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 6 papers in Immunology and 5 papers in Rheumatology. Recurrent topics in John Ervin's work include Respiratory viral infections research (10 papers), Osteoarthritis Treatment and Mechanisms (5 papers) and Influenza Virus Research Studies (4 papers). John Ervin is often cited by papers focused on Respiratory viral infections research (10 papers), Osteoarthritis Treatment and Mechanisms (5 papers) and Influenza Virus Research Studies (4 papers). John Ervin collaborates with scholars based in United States, Belgium and Netherlands. John Ervin's co-authors include Alan Kivitz, Paul J. Tiseo, Scott Mellis, Haobo Ren, Robin Burges, P Hanson, Randall M. Stevens, James N. Campbell, Michael Lock and Cynthia Strout and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Pain.

In The Last Decade

John Ervin

20 papers receiving 652 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults

2023 90 citations Ann R. Falsey, Kristi L. Williams et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Ervin United States	13	270	179	133	104	95	20	677
M Ramam India	21	368 1.4×	221 1.2×	111 0.8×	63 0.6×	51 0.5×	102	1.2k
Kin Fon Leong Malaysia	18	340 1.3×	225 1.3×	67 0.5×	94 0.9×	30 0.3×	69	985
Aparna Palit India	14	135 0.5×	169 0.9×	57 0.4×	92 0.9×	34 0.4×	98	739
Andrea Marchegiani Italy	16	136 0.5×	161 0.9×	55 0.4×	161 1.5×	79 0.8×	78	780
Athanassios Kolivras Belgium	14	165 0.6×	222 1.2×	67 0.5×	91 0.9×	31 0.3×	46	670
P. Goldschmidt France	21	291 1.1×	78 0.4×	30 0.2×	153 1.5×	59 0.6×	80	1.1k
Baochang Fan United States	9	284 1.1×	112 0.6×	120 0.9×	242 2.3×	16 0.2×	16	676
Manon Paradis Canada	19	159 0.6×	249 1.4×	39 0.3×	83 0.8×	40 0.4×	32	802
Jin Ho Choe South Korea	16	198 0.7×	92 0.5×	154 1.2×	149 1.4×	28 0.3×	33	648
Sueli Donizete Borelli Brazil	14	318 1.2×	150 0.8×	58 0.4×	88 0.8×	28 0.3×	61	828

Countries citing papers authored by John Ervin

Since Specialization

Citations

This map shows the geographic impact of John Ervin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Ervin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Ervin more than expected).

Fields of papers citing papers by John Ervin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Ervin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Ervin. The network helps show where John Ervin may publish in the future.

Co-authorship network of co-authors of John Ervin

This figure shows the co-authorship network connecting the top 25 collaborators of John Ervin. A scholar is included among the top collaborators of John Ervin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Ervin. John Ervin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schunk, Mirjam, John Ervin, Christoph Schindler, et al.. (2024). A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity. Human Vaccines & Immunotherapeutics. 20(1). 2410574–2410574. 3 indexed citations

Schwarz, Tino F., Chiu-Shong Liu, Kenji Takazawa, et al.. (2023). Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial. The Journal of Infectious Diseases. 230(1). e102–e110. 16 indexed citations

Tricou, Vianney, Brandon Essink, John Ervin, et al.. (2023). Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. PLoS neglected tropical diseases. 17(3). e0011124–e0011124. 16 indexed citations

Falsey, Ann R., Kristi L. Williams, Stephan Bart, et al.. (2023). Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults. New England Journal of Medicine. 388(7). 609–620. 90 indexed citations breakdown →

Khanna, Dinesh, Paul H. Caldron, Richard W. Martin, et al.. (2022). Adipose‐Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. Arthritis & Rheumatology. 74(8). 1399–1408. 20 indexed citations

Comeaux, Christy, Ann R. Falsey, Kristi Williams, et al.. (2022). 2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level. Open Forum Infectious Diseases. 9(Supplement_2). 2 indexed citations

Schwarz, Tino F., Chiu-Shong Liu, Kenji Takazawa, et al.. (2022). 96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination. Open Forum Infectious Diseases. 9(Supplement_2). 4 indexed citations

Schwarz, Tino F., Chiu-Shong Liu, Kenji Takazawa, et al.. (2022). 119. Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination. Open Forum Infectious Diseases. 9(Supplement_2). 2 indexed citations

Buchwald, Ulrike K., Charles P. Andrews, John Ervin, et al.. (2021). Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older. Human Vaccines & Immunotherapeutics. 17(8). 2678–2690. 10 indexed citations

10.

Falsey, Ann R., Kristi L. Williams, Stephan Bart, et al.. (2021). LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study. Open Forum Infectious Diseases. 8(Supplement_1). S812–S812. 10 indexed citations

11.

Frenck, Robert W., John Ervin, Laurence Chu, et al.. (2019). Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial. The Lancet Infectious Diseases. 19(6). 631–640. 57 indexed citations

12.

Stevens, Randall M., et al.. (2019). Randomized, Double‐Blind, Placebo‐Controlled Trial of Intraarticular Trans ‐ Capsaicin for Pain Associated With Osteoarthritis of the Knee. Arthritis & Rheumatology. 71(9). 1524–1533. 84 indexed citations

13.

Falloon, Judith, H. Keipp Talbot, Craig Curtis, et al.. (2017). Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses. Clinical and Vaccine Immunology. 24(9). 30 indexed citations

14.

Stevens, Randall M., et al.. (2017). OP0167 Efficacy and safety of CNTX-4975 in subjects with moderate to severe osteoarthritis knee pain: 24-week, randomized, double-blind, placebo-controlled, dose-ranging study. Annals of the Rheumatic Diseases. 76. 121–121. 10 indexed citations

15.

Ervin, John, Donald M. Brandon, Eduardo Forleo‐Neto, et al.. (2015). Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial. International Journal of Infectious Diseases. 41. 65–72. 26 indexed citations

16.

Tiseo, Paul J., Alan Kivitz, John Ervin, Haobo Ren, & Scott Mellis. (2014). Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: Results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. Pain. 155(7). 1245–1252. 88 indexed citations

17.

Bar‐Or, David, Kristin Salottolo, Matthew J. Phillips, et al.. (2014). A Randomized Clinical Trial to Evaluate Two Doses of an Intra-Articular Injection of LMWF-5A in Adults with Pain Due to Osteoarthritis of the Knee. PLoS ONE. 9(2). e87910–e87910. 41 indexed citations

18.

Gurwith, Marc, Michael Lock, Eve M. Taylor, et al.. (2013). Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. The Lancet Infectious Diseases. 13(3). 238–250. 122 indexed citations

19.

Gorse, Geoffrey J., Ann R. Falsey, Dennis Morrison, et al.. (2013). Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18–64 years of age. Vaccine. 31(50). 6034–6040. 16 indexed citations

20.

Schnitzer, Thomas J., Jean‐Pierre Pelletier, John Ervin, et al.. (2011). Civamide Cream 0.075% in Patients with Osteoarthritis of the Knee: A 12-Week Randomized Controlled Clinical Trial with a Longterm Extension. The Journal of Rheumatology. 39(3). 610–620. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact